ABVX

7 atoms · 跨 3 天 · 首见 2026-06-01 · 最近 2026-06-18

三色: 🟦 fact 5 · 🟥 take 2 · stance ▲4/▼1/◆0

来源: 群 1 · X 6

时态: fresh:6 · aging:1

标签: 好数字:4 · 好观点:2 · 好信源:2

叙事 (narrative) (1)

• 2026-06-01 · after-market buzz
  After-market buzz! $ABVX
  tags: 好观点 · → daily

立场 (position) (1)

• 2026-06-18 [老化中] · 逢低买入博弈LLY收购
  ABVX 逢低买入，博弈 LLY 收购
  tags: 好观点·好信源 · → daily

事实 (fact) (5)

• 2026-06-02 · Jefferies评级
  $ABVX was downgraded to Hold at Jefferies after Phase 3 ABTECT UC maintenance data.
  tags: 好信源 · → daily
  value: direction=下调至持有
• 2026-06-01 · Phase 3 临床缓解率
  At Week 44, clinical remission was 50.8% for 25 mg and 51.3% for 50 mg vs 10.4% for placebo.
  tags: 好数字 · → daily
  value: qty=50.8% · date=Week 44 · dose=25 mg
• 2026-06-01 · Phase 3 主要终点达成
  Both doses met the primary endpoint and all key secondary endpoints, including endoscopic improvement, endoscopic remission, corticosteroid-free clinical remission, and sustained clinical remission.
  tags: 好数字 · → daily
• 2026-06-01 · 安全性信号
  No new safety signals were observed
  tags: 好数字 · → daily
• 2026-06-01 · NDA 提交计划
  Abivax plans to file an NDA with the FDA in late Q4 2026.
  tags: 好数字 · → daily
  value: date=late Q4 2026

时间轴 (近 20)

• 2026-06-18 · position · 逢低买入博弈LLY收购 · → daily
• 2026-06-02 · fact · Jefferies评级 · → daily
• 2026-06-01 · fact · Phase 3 临床缓解率 · → daily
• 2026-06-01 · fact · Phase 3 主要终点达成 · → daily
• 2026-06-01 · fact · 安全性信号 · → daily
• 2026-06-01 · fact · NDA 提交计划 · → daily
• 2026-06-01 · narrative · after-market buzz · → daily

← 实体目录 · 系统日志